Allianz Asset Management GmbH decreased its stake in shares of Masimo Co. (NASDAQ:MASI) by 17.1% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 142,825 shares of the medical equipment provider’s stock after selling 29,368 shares during the period. Allianz Asset Management GmbH owned 0.27% of Masimo worth $17,788,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Massachusetts Financial Services Co. MA increased its stake in shares of Masimo by 101.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 224,475 shares of the medical equipment provider’s stock worth $21,920,000 after acquiring an additional 113,248 shares during the period. Alps Advisors Inc. acquired a new position in shares of Masimo during the second quarter worth about $457,000. TD Asset Management Inc. acquired a new position in shares of Masimo during the second quarter worth about $2,714,000. Crossmark Global Holdings Inc. increased its stake in shares of Masimo by 14.4% during the second quarter. Crossmark Global Holdings Inc. now owns 7,636 shares of the medical equipment provider’s stock worth $746,000 after acquiring an additional 960 shares during the period. Finally, First Trust Advisors LP increased its stake in shares of Masimo by 215.9% during the second quarter. First Trust Advisors LP now owns 11,206 shares of the medical equipment provider’s stock worth $1,094,000 after acquiring an additional 7,659 shares during the period. 82.74% of the stock is currently owned by institutional investors and hedge funds.
In other Masimo news, COO Anand Sampath sold 30,000 shares of the company’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $110.00, for a total transaction of $3,300,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joe E. Kiani sold 200,555 shares of the company’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $122.92, for a total transaction of $24,652,220.60. The disclosure for this sale can be found here. Insiders have sold 309,180 shares of company stock worth $37,570,849 over the last 90 days. 12.60% of the stock is currently owned by company insiders.
Several research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a research report on Friday, November 16th. BidaskClub lowered shares of Masimo from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. UBS Group assumed coverage on shares of Masimo in a research report on Tuesday, November 27th. They set a “buy” rating and a $137.00 target price on the stock. Piper Jaffray Companies upped their target price on shares of Masimo to $120.00 and gave the stock a “neutral” rating in a research report on Thursday, November 1st. Finally, Stifel Nicolaus upped their target price on shares of Masimo from $112.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 2nd. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $119.00.
Shares of MASI opened at $105.30 on Friday. Masimo Co. has a twelve month low of $80.69 and a twelve month high of $126.89. The stock has a market cap of $5.74 billion, a price-to-earnings ratio of 42.98, a P/E/G ratio of 2.38 and a beta of 1.07.
Masimo (NASDAQ:MASI) last issued its earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.02. Masimo had a net margin of 17.08% and a return on equity of 20.29%. The company had revenue of $210.58 million for the quarter, compared to analyst estimates of $207.62 million. During the same period in the prior year, the business posted $0.56 earnings per share. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. Equities analysts anticipate that Masimo Co. will post 2.92 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Allianz Asset Management GmbH Sells 29,368 Shares of Masimo Co. (MASI)” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/12/08/allianz-asset-management-gmbh-sells-29368-shares-of-masimo-co-masi.html.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Further Reading: What Does Beta Mean In Stock Selection
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.